Halia Therapeutics Doses First Healthy Volunteer with Oral LRRK2 Inhibitor HT-4253 for Alzheimer's
核心洞察
Halia Therapeutics (搜索) initiated a Phase 1 clinical trial for HT-4253, a novel oral LRRK2 (搜索) inhibitor, with the first healthy volunteer dosed.
The trial (NCT06537817) is a randomized, placebo-controlled, double-blind study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of HT-4253.
HT-4253 targets LRRK2 (搜索) to reduce neuroinflammation, potentially preventing or delaying Alzheimer's onset, especially in individuals with the APOE4 genotype.
Halia Therapeutics (搜索) has announced the dosing of the first healthy volunteer in a Phase 1 clinical trial of HT-4253, a novel oral LRRK2 (搜索) inhibitor being developed as a potential treatment for Alzheimer's Disease (搜索). The study, a first-in-human trial, aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HT-4253.
The Phase 1 trial (NCT06537817) employs a randomized, placebo-controlled, double-blind design, utilizing single ascending dose (SAD) and multiple ascending dose (MAD) formats. The primary objective is to assess the drug's ability to inhibit LRRK2 (搜索), a critical enzyme implicated in neuroinflammation.
Rationale Behind LRRK2 Inhibition
Recent genetic studies have identified variants in the Rab10 gene that appear to protect individuals carrying the APOE4 genotype, a significant risk factor for Alzheimer's disease (搜索). These protective variants inhibit Rab10, a protein activated by LRRK2 (搜索), leading to reduced neuroinflammation and neuroprotection. HT-4253 is designed to mimic these Rab10 variants by blocking LRRK2, thereby preventing Rab10 activation and potentially preventing or delaying the onset of Alzheimer's in APOE4 carriers.
HT-4253: A Potential Disease-Modifying Agent
HT-4253 is an orally administered small molecule with demonstrated brain penetration. By targeting LRRK2 (搜索), a key mediator of neuroinflammation, HT-4253 aims to address the chronic brain inflammation that drives neurodegenerative diseases like Parkinson's (搜索) and Alzheimer's. Preclinical studies by Halia scientists suggest that LRRK2 plays a crucial role in regulating neuroinflammation, making its inhibition a promising therapeutic strategy.
Halia Therapeutics' Broader Pipeline
Halia Therapeutics (搜索) is also developing HT-6184, a NEK7 (搜索)/NLRP3 (搜索) inhibitor, which has completed a Phase I study (NCT05447546) and a Phase II trial assessing its impact on post-procedure diagnostic biomarkers of inflammation and pain (NCT06241742). The company is currently conducting a Phase II trial to evaluate HT-6184's efficacy in treating lower-risk myelodysplastic syndromes (搜索) (LR-MDS).
"Dosing the first subject in the Phase 1 trial of HT-4253 marks a significant step in the fight against neurodegenerative diseases such as Alzheimer's disease (搜索)," said Dr. David Bearss, CEO of Halia Therapeutics (搜索). "We believe that HT-4253 will provide a groundbreaking treatment option for patients who currently have few choices to prevent or delay Alzheimer's onset, as the drug targets the underlying neuroinflammation linked to causing neurocognitive disease."